GlobeNewswire: Madrigal Pharmaceuticals, Inc. Contains the last 10 of 123 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:42:46ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/19/2848267/0/en/Madrigal-Pharmaceuticals-Announces-Pricing-of-Upsized-600-Million-Public-Offering.html?f=22&fvtc=4&fvtv=29204Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering2024-03-19T03:58:56Z<![CDATA[CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the pricing of its underwritten public offering of 750,000 shares of its common stock at a public offering price of $260.0000 per share, and, to certain investors, pre-funded warrants to purchase 1,557,692 shares of common stock at a price of $259.9999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The size of the offering was increased by $100 million subsequent to the initial announcement of the offering. The gross proceeds to Madrigal from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $600 million. Madrigal has granted the underwriters of the offering a 30-day option to purchase up to an additional 346,153 shares of common stock from the company at the public offering price, less underwriting discounts and commissions.]]>https://www.globenewswire.com/news-release/2024/03/18/2848146/0/en/Madrigal-Pharmaceuticals-Announces-Proposed-Public-Offering.html?f=22&fvtc=4&fvtv=29204Madrigal Pharmaceuticals Announces Proposed Public Offering2024-03-18T20:04:05Z<![CDATA[CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that it has commenced an underwritten public offering of $500 million in shares of its common stock and pre-funded warrants to purchase common stock. The purchase price of each pre-funded warrant will equal the price per share at which shares of common stock are being sold to the public in this offering, minus $0.0001, which will be the per share exercise price of each pre-funded warrant. Madrigal also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. All of the shares in the proposed offering are to be sold by Madrigal.]]>https://www.globenewswire.com/news-release/2024/03/14/2846708/0/en/Madrigal-Pharmaceuticals-Announces-FDA-Approval-of-Rezdiffra-resmetirom-for-the-Treatment-of-Patients-with-Noncirrhotic-Nonalcoholic-Steatohepatitis-NASH-with-Moderate-to-Advanced-.html?f=22&fvtc=4&fvtv=29204Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis2024-03-14T20:15:00Z<![CDATA[CONSHOHOCKEN, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). Continued approval for this indication may be contingent upon verification and description of clinical benefit in ongoing confirmatory trials.]]>Rezdiffra product imageRezdiffrahttps://www.globenewswire.com/news-release/2024/03/06/2841769/0/en/Madrigal-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=29204Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)2024-03-06T21:05:00Z<![CDATA[CONSHOHOCKEN, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to (i) Mardi C. Dier, the Company’s new Senior Vice President and Chief Financial Officer, effective March 11, 2024 and (ii) 39 other new employees, in each case with a grant date of March 1, 2024, as equity inducement awards under the terms of the company's 2023 Inducement Plan. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2024/03/05/2840401/0/en/Madrigal-Pharmaceuticals-Announces-EMA-Validation-of-its-Marketing-Authorization-Application-for-Resmetirom-for-the-Treatment-of-NASH-MASH-with-Liver-Fibrosis.html?f=22&fvtc=4&fvtv=29204Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis2024-03-05T13:00:00Z<![CDATA[CONSHOHOCKEN, Pa., March 05, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the Company’s Marketing Authorization Application (MAA) for resmetirom for the treatment of NASH/metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis has been validated and is now under evaluation with the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).]]>https://www.globenewswire.com/news-release/2024/02/28/2836822/0/en/Madrigal-Pharmaceuticals-Appoints-Mardi-C-Dier-as-Chief-Financial-Officer.html?f=22&fvtc=4&fvtv=29204Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer2024-02-28T12:01:00Z<![CDATA[CONSHOHOCKEN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Mardi C. Dier has been appointed Chief Financial Officer.]]>https://www.globenewswire.com/news-release/2024/02/28/2836803/0/en/Madrigal-Pharmaceuticals-Provides-Corporate-Updates-and-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=29204Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results2024-02-28T12:00:00Z<![CDATA[CONSHOHOCKEN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of corporate updates and reports fourth quarter and full year 2023 financial results.]]>https://www.globenewswire.com/news-release/2024/02/21/2832698/0/en/Madrigal-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=29204Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)2024-02-21T13:00:00Z<![CDATA[CONSHOHOCKEN, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 46 new employees, in each case with a grant date of February 15, 2024, as equity inducement awards under the terms of the company's 2023 Inducement Plan. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2024/02/08/2825978/0/en/Madrigal-Pharmaceuticals-Announces-Publication-of-the-Phase-3-MAESTRO-NASH-Trial-of-Resmetirom-in-the-New-England-Journal-of-Medicine.html?f=22&fvtc=4&fvtv=29204Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine2024-02-08T13:00:00Z<![CDATA[CONSHOHOCKEN, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the publication of the pivotal Phase 3 MAESTRO-NASH trial of resmetirom in the New England Journal of Medicine.]]>https://www.globenewswire.com/news-release/2024/02/06/2824720/0/en/Madrigal-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=29204Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)2024-02-06T21:05:00Z<![CDATA[CONSHOHOCKEN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to seven new employees, in each case with a grant date of February 1, 2024, as equity inducement awards under the terms of the company's 2023 Inducement Plan. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).]]>